ArticleBMC cancer2025

Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies.

Qing Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.